Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Overexpression and pre-treatment of recombinant human Secretory Leukocyte Protease Inhibitor (rhSLPI) reduces an in vitro ischemia/reperfusion injury in rat cardiac myoblast (H9c2) cell

Overexpression and pre-treatment of recombinant human Secretory Leukocyte Protease Inhibitor... AbstractOne of the major causes of cardiac cell death during myocardial ischemia is the oversecretion of protease enzymes surrounding the ischemic tissue. Therefore, inhibition of the protease activity could be an alternative strategy for preventing the expansion of the injured area. In the present study, we investigated the effects of Secretory Leukocyte Protease Inhibitor (SLPI), by means of overexpression and treatment of recombinant human SLPI (rhSLPI) in an in vitro model. Rat cardiac myoblast (H9c2) cells overexpressing rhSLPI were generated by gene delivery using pCMV2-SLPI-HA plasmid. The rhSLPI-H9c2 cells, mock transfected cells, and wild-type (WT) control were subjected to simulated ischemia/reperfusion (sI/R). Moreover, the treatment of rhSLPI in H9c2 cells was also performed under sI/R conditions. The results showed that overexpression of rhSLPI in H9c2 cells significantly reduced sI/R-induced cell death and injury, intracellular ROS level, and increased Akt phosphorylation, when compared to WT and mock transfection (p <0.05). Treatment of rhSLPI prior to sI/R reduced cardiac cell death and injury, and intra-cellular ROS level. In addition, 400 ng/ml rhSLPI treatment, prior to sI, significantly inhibited p38 MAPK phosphorylation and rhSLPI at 400–1000 ng/ml could increase Akt phosphorylation. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Biomolecular Concepts de Gruyter

Overexpression and pre-treatment of recombinant human Secretory Leukocyte Protease Inhibitor (rhSLPI) reduces an in vitro ischemia/reperfusion injury in rat cardiac myoblast (H9c2) cell

Download PDF
16 pages

Loading next page...
 
/lp/degruyter/overexpression-and-pre-treatment-of-recombinant-human-secretory-KGHptYtsaa
Publisher
de Gruyter
Copyright
© 2018 Eakkapote Prompunt et al., published by De Gruyter
ISSN
1868-503X
eISSN
1868-503X
DOI
10.1515/bmc-2018-0004
pmid
29729136
Publisher site
See Article on Publisher Site

Abstract

AbstractOne of the major causes of cardiac cell death during myocardial ischemia is the oversecretion of protease enzymes surrounding the ischemic tissue. Therefore, inhibition of the protease activity could be an alternative strategy for preventing the expansion of the injured area. In the present study, we investigated the effects of Secretory Leukocyte Protease Inhibitor (SLPI), by means of overexpression and treatment of recombinant human SLPI (rhSLPI) in an in vitro model. Rat cardiac myoblast (H9c2) cells overexpressing rhSLPI were generated by gene delivery using pCMV2-SLPI-HA plasmid. The rhSLPI-H9c2 cells, mock transfected cells, and wild-type (WT) control were subjected to simulated ischemia/reperfusion (sI/R). Moreover, the treatment of rhSLPI in H9c2 cells was also performed under sI/R conditions. The results showed that overexpression of rhSLPI in H9c2 cells significantly reduced sI/R-induced cell death and injury, intracellular ROS level, and increased Akt phosphorylation, when compared to WT and mock transfection (p <0.05). Treatment of rhSLPI prior to sI/R reduced cardiac cell death and injury, and intra-cellular ROS level. In addition, 400 ng/ml rhSLPI treatment, prior to sI, significantly inhibited p38 MAPK phosphorylation and rhSLPI at 400–1000 ng/ml could increase Akt phosphorylation.

Journal

Biomolecular Concepts – de Gruyter

Published: May 4, 2018

References

  • Morphological, biochemical, and electrophysiological characterization of a clonal cell (H9c2) line from rat heart
  • Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli
  • The cellular and molecular origin of reactive oxygen species generation during myocardial ischemia and reperfusion
  • Novel role for SLPI in MOG-induced EAE revealed by spinal cord expression analysis
  • Myocardial ischemia-reperfusion injury, antioxidant enzyme systems, and selenium: a review
  • The cell biology of acute myocardial ischemia
  • A chemical genetic approach reveals that p38alpha MAPK activation by diphosphorylation aggravates myocardial infarction and is prevented by the direct binding of SB203580
  • Secretory leukocyte protease inhibitor in mice regulates local and remote organ inflammatory injury induced by hepatic ischemia/reperfusion
  • Effect of a neutrophil elastase inhibitor (ONO-5046 Na) on ischemia/reperfusion injury using the left-sided heterotopic canine heart transplantation model
  • Morphological, biochemical, and electrophysiological characterization of a clonal cell (H9c2) line from rat heart
  • Inhibition of p38 reduces myocardial infarction injury in the mouse but not pig after ischemia-reperfusion
  • Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion
  • Myocardial reperfusion injury: etiology, mechanisms, and therapies
  • The cellular and molecular origin of reactive oxygen species generation during myocardial ischemia and reperfusion
  • An in vitro endothelial cell protective effect of secretory leukocyte protease inhibitor against simulated ischaemia/reperfusion injury
  • Secretory leukocyte protease inhibitor interferes with uptake of lipopolysaccharide by macrophages
  • Recombinant secretory leukoprotease inhibitor augments glutathione levels in lung epithelial lining fluid